Update shared on15 Aug 2025
Fair value Increased 66%The significant increase in consensus analyst price target for ArcticZymes Technologies is primarily driven by notably higher forecasts for revenue growth and a rising future P/E multiple, resulting in an upward revision from NOK17.50 to NOK24.50.
What's in the News
- Launched M-SAN HQ GMP, a new GMP-grade nuclease tailored for viral vector manufacturing, enabling high activity in physiological salt conditions and improving DNA removal without harsh buffers.
- The new product is positioned to support advanced therapies like in vivo CAR-T and vaccines, addressing regulatory needs for nuclease and host cell DNA contamination reduction.
- Extended a three-year research partnership with the Austrian Centre of Industrial Biotechnology (acib) to enhance purification methods for bionanoparticles, critical for gene therapies and cancer treatments.
- Demonstrated that ArcticZymes’ M-SAN enzyme outperforms conventional nucleases in digesting chromatin under process-relevant conditions, strengthening product differentiation in bioprocessing.
- Collaboration will focus on optimizing high-salt nuclease treatments, developing improved chromatin detection methods, and fostering enzyme innovation, backed by industry-academic funding and PhD training initiatives.
Valuation Changes
Summary of Valuation Changes for ArcticZymes Technologies
- The Consensus Analyst Price Target has significantly risen from NOK17.50 to NOK24.50.
- The Future P/E for ArcticZymes Technologies has significantly risen from 33.09x to 41.93x.
- The Consensus Revenue Growth forecasts for ArcticZymes Technologies has significantly risen from 15.5% per annum to 18.7% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.